Pharmaceutical Industry News | The Pharmaletter
WEBSep 2, 2024 · Jazz Pharma raises $850 million through note offering. Jazz Pharmaceuticals (Nasdaq: JAZZ) is to raise $850 million with the pricing of exchangeable senior notes, due 2030. 4 September 2024.
Pharma, Biotech and Generics Industry News | The Pharmaletter
WEBSep 3, 2024 · Generics. 7 August 2024 US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. Belgium’s largest drugmaker UCB announced a strategic divestment …
Study shows Fostair has comparable efficacy to Seretide in asthma ...
WEBJan 20, 2014 · A study has shown that asthma patients may be switched from Seretide (fluticasone propionate-salmeterol [FP-SAL]) to Fostair (extra-fine beclomethasone-formoterol [efBDP-FOR]) at an equivalent or lower inhaled corticosteroid (ICS) dosage with no reduction in clinical effectiveness but a significant reduction in cost to the UK’s National Health Service (NHS).
Aspire advances growth with acquisition of Cenoté Pharma
WEBGenerics. 11 March 2024. Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. No terms of the financial agreement were disclosed by either party. Cenoté Pharma is a category specialist in carnitine deficiencies.
SFJ Pharma closes transfer of bentracimab assets from PhaseBio
WEBJan 18, 2023 · SFJ Pharmaceuticals is claiming victory in its legal dispute with cardiopulmonary diseases focussed US firm PhaseBio Pharmaceuticals (Nasdaq: PHAS) regarding a blood thinner reversal agent, announcing the closing of the sale and transfer of assets related to bentracimab from PhaseBio to SFJ, a California-based drug development company backed by Blackstone Life Sciences and Abingworth.
About The Pharma Letter | The Pharmaletter
WEBSep 8, 2024 · The Pharma Letter offers high value news and insights for people with a professional interest in the global pharmaceutical, biotech, generic and biosimilar industries. Headquartered in London, the company draws from a network of foreign correspondents, with healthcare journalists around the world providing insight on local markets.
BRIEF—Shorla and Eversana launch Jylamvo | Pharmaceutical | The ...
WEBPharmaceutical. 19 December 2023. Irish-American specialty pharma company Shorla Oncology and Eversana, a provider of commercialization services to the life sciences industry, have announced the US commercial launch of Jylamvo (methotrexate) oral solution, the first and only oral methotrexate solution approved in the USA for use in adults.
Tackling Europe's 'triple A' challenge: a bold ambition of EU's …
WEBSep 29, 2023 · Addressing what has been dubbed the ‘triple A’ challenge of access, affordability and availability has been an objective of the European Medicines Agency (EMA) for nearly 30 years, going back to the launch of the centralized procedure in 1995.
Roquefort Therapeutics leaps on news term sheet for licencing …
WEBMay 23, 2024 · Shares of UK immune-oncology company Roquefort Therapeutics (LSE: ROQ) rose almost 24% to 5.51 pence this morning, following the signing of a term sheet to out-license its Midkine antibody portfolio to Dubai-based PDC. PDC is a leading MEA pharmaceutical research and development organization which …
The state of pharma mergers and acquisitions in 2018
WEBSep 12, 2018 · In the age of spiralling research and development costs and the pressure to minimize risk and maximize reward in bringing new drugs to market, the pharmaceutical industry’s biggest players increasingly look to smaller companies with innovative pipelines to bolster their own portfolios and maximize profits.
Skip to content